SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of...
Latest News
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update follows a recent...
THOUSAND OAKS, Calif. — Capsida Biotherapeutics today announced new preclinical data supporting the potential of Capsida’s gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations. Gene therapy for genetic epilepsy due to STXBP1...
Capsida previously received FDA Orphan Drug Designation and IND clearance to initiate the SYNRGY Phase 1/2a clinical trial for CAP-002 THOUSAND OAKS, Calif. — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its CAP-002 program. CAP-002 is the company’s investigational...
San Francisco, California – Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology. A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being...
Basel, Switzerland – Chimeric antigen receptor (CAR) T-cell therapy represents one of the most significant advancements in modern immunotherapy. Originally developed to treat hematologic malignancies, this approach involves genetically modifying a patient’s T cells to express an artificial receptor capable of recognizing specific tumor antigens. Upon re-infusion, these tailored T...
HOUSTON, Texas – Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer. The therapy...
Among patients with refractory large B cell lymphoma (LBCL), chimeric antigen receptor (CAR)-T cell therapy appears to yield superior long-term clinical outcomes to those seen with standard salvage therapy regimens, according to an analysis published in Blood Advances. Treatments for LBCL, the most common non-Hodgkin lymphoma subtype, have improved over the...
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated effectiveness and safety in relapsed/refractory multiple myeloma (RRMM), according to a meta-analysis published in the International Journal of Medical Sciences. RRMM treatments have come a long way and have drastically improved overall survival, but the disease remains incurable. CAR-T therapy has led to...
STAMFORD, Conn. — Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program....